RICHLAND, Wash., June 20, 2017 /PRNewswire/ -- IsoRay, Inc.
(NYSE MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced the publication of a study entitled,
"Clinical Outcomes of Large Brain Metastases Treated with
Neurosurgical Resection and Intraoperative Cesium-131
Brachytherapy: Results of a Prospective Trial" in the highly
respected International Journal of Radiation Oncology, Biology,
Physics (the 'Red Journal')."
The study was published on the Red Journal's website on
June 12, 2017. The study was
conducted by Gabriella A. Wernicke, M.D., M.Sc. and Theodore H. Schwartz M.D., of the Stich
Radiation Oncology Center and Department of Neurosurgery, Brain and
Spine Center, Weill Cornell Medical College/New York-Presbyterian
Hospital, NYC, NY.
The study assessed the impact of permanent low-dose rate
Cesium-131 brachytherapy on local control and radionecrosis (RN) in
patients treated for large brain metastases. Forty-two patients
with a total of 46 metastases >2.0 cm in preoperative diameter
were accrued onto a prospective trial between 2010 and 2015.
Patients underwent surgical resection with intra-operative
placement of stranded Cesium-131 seeds as permanent volume implants
in the resection cavity.
The study demonstrated a 100% freedom from local progression
rate, meaning that the surgically removed brain metastases did not
re-grow. In addition, there was a 0% rate of radionecrosis, a
significant side effect of radiation therapy to the brain.
Radiation necrosis is especially problematic when larger brain
metastases (with diameters 2 cm or larger) are treated with
radiation.
The study's authors concluded that intraoperative Cesium-131
brachytherapy is a safe and effective adjuvant therapy for large
brain metastases requiring neurosurgical intervention.
Bill Cavanagh, Chief Scientific
Officer of IsoRay, Inc. commented, "Evidence of Cesium-131's
efficacy in treating brain cancer continues to increase as
supported by this important study. The work of Drs. Wernicke
and Schwartz is truly pioneering and provides hope that we can
continue to improve the available treatment for those afflicted
with brain metastases. Treatment of brain metastases is a large
unmet need and we're gratified that our Cesium-131 product has
promise to be effective for the many in need."
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter@IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay, Inc.'s future
expectations, including: the advantages of our products and their
delivery systems, whether the study will ultimately be completed,
whether Cs-131 therapy will demonstrate disease control in large
brain metastasis, and the perception by the patient of quality of
life outcomes or prove to be a safe approach compared to other
treatment options, and all other statements in this release, other
than historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released and
support the conclusions of past studies, whether ongoing patient
quality of life results with our products are favorable and in line
with the conclusions of clinical studies and initial patient
results, patient results achieved when our products are used for
the treatment of cancers and malignant diseases in conjunction with
other treatments, successful completion of future research and
development activities, whether we, our distributors, and our
customers will successfully obtain and maintain all required
regulatory approvals and licenses to market, sell, and use our
products in its various forms, continued compliance with ISO
standards as audited by BSI, the success of our sales and marketing
efforts, changes in reimbursement rates, changes in laws and
regulations applicable to our products, and other risks detailed
from time to time in IsoRay, Inc.'s reports filed with the
SECSecurities and Exchange Commission. Unless required to do so by
law, the Company, IsoRay, Inc. undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isoray-announces-study-published-in-the-international-journal-of-radiation-oncology-biology-physics-entitled-clinical-outcomes-of-large-brain-metastases-treated-with-neurosurgical-resection-and-intraoperative-cesium-131-brachy-300476435.html
SOURCE IsoRay, Inc.